AVN 67.54 No Change ▼ 0.00 (0%)
BOP 9.35 No Change ▼ 0.00 (0%)
CHCC 139.27 No Change ▼ 0.00 (0%)
DCL 10.89 No Change ▼ 0.00 (0%)
DGKC 112.94 No Change ▼ 0.00 (0%)
EFERT 66.44 No Change ▼ 0.00 (0%)
EPCL 45.64 No Change ▼ 0.00 (0%)
FCCL 20.50 No Change ▼ 0.00 (0%)
FFL 15.93 No Change ▼ 0.00 (0%)
HASCOL 15.78 No Change ▼ 0.00 (0%)
HBL 139.52 No Change ▼ 0.00 (0%)
HUBC 76.40 No Change ▼ 0.00 (0%)
HUMNL 8.09 No Change ▼ 0.00 (0%)
JSCL 27.18 No Change ▼ 0.00 (0%)
KAPCO 28.53 No Change ▼ 0.00 (0%)
KEL 3.89 No Change ▼ 0.00 (0%)
LOTCHEM 12.30 No Change ▼ 0.00 (0%)
MLCF 41.45 No Change ▼ 0.00 (0%)
OGDC 98.35 No Change ▼ 0.00 (0%)
PAEL 36.09 No Change ▼ 0.00 (0%)
PIBTL 13.27 No Change ▼ 0.00 (0%)
PIOC 98.87 No Change ▼ 0.00 (0%)
POWER 9.38 No Change ▼ 0.00 (0%)
PPL 86.77 No Change ▼ 0.00 (0%)
PSO 209.04 No Change ▼ 0.00 (0%)
SNGP 57.36 No Change ▼ 0.00 (0%)
STPL 12.67 No Change ▼ 0.00 (0%)
TRG 50.01 No Change ▼ 0.00 (0%)
UNITY 21.51 No Change ▼ 0.00 (0%)
CASES 327,063 847
DEATHS 6,727 12

ISLAMABAD: Pakistan on Tuesday announced the launch of phase three clinical trials of coronavirus vaccine in collaboration with China’s CanSino Biologics.

Addressing a press conference, Special Assistant to the Prime Minister (SAPM) on Health Dr Faisal Sultan alongside National Health Institute (NIH) Executive Director Major General Aamer Ikram at the National Command and Operation Centre (NCOC) said that Pakistan was taking part in the important step to develop Covid-19 vaccine.

Trials for phase 1 and 2 for the vaccine were held in China.

Pakistan, under a public-private partnership between the NIH and CanSino, is among the countries, which will carry out phase 3, they said.

The Drug Regulatory Authority Pakistan (DRAP) which regulates the matters related to drugs in Pakistan last month gave the go-ahead for the country’s first phase 3 clinical trial for CanSino’s candidate.

Planning, Development and Special Initiatives Minister Asad Umar said that 40,000 people would participate in the trial, which was being held in seven countries across the world.

Around 8,000 to 10,000 of these will be from Pakistan, he said. Maj Gen Ikram said it was an "honour" for the country that it was participating in the phase 3 trial of a vaccine for the first time. "The entire world is looking towards a vaccine right now. There are seven vaccines for which trials are being conducted, three of them developed in China. This CanSino vaccine is based on recombinant technology in which an adino-vector is made deficient. The virus vector and cell culture has been procured from Canada," he said.

Speaking about how the study is conducted, he said that in the pre-clinical phase, the vaccine is tried on animals.

"This was done in China at the start of the year. It was safe and immunogenic.”

"Then there is a phase 1 trial which was again conducted in China and its results were good. In this phase, the safety and efficacy [of the vaccine] on the human body is looked at.”

He added that the technology for the CanSino vaccine was similar to that of the Oxford vaccine being developed by Astra-Zeneca.

A chimpanzee adino-vector was used in the AstraZeneca vaccine, while a human adino-vector was used for this vaccine, he disclosed. He said phase 3 trial was the biggest and most difficult stage. "The NIH has accepted this challenge and we are grateful to the patronage of the NCOC and the Ministry of Health." He said that the trials have been launched from today and 8,000 to 10,000 volunteers would be inducted through a formal system.

A medical examination of the volunteers would be carried out after which the vaccine would be administered to them.

Ikram added that the NIH would follow up with them for 12 months but the results of the vaccine would be expected in three months. The vaccine would be available in the market in five to six months, once its results were analysed and it was approved, said Ikram. "This is the vaccine that has already been approved and is being administered to army officials and policemen in China. Therefore, its safety is ensured," he concluded.

Copyright Business Recorder, 2020